Step 1 topics → Endocrine → SGLT2 Inhibitors

SGLT2 Inhibitors

USMLE Step 1 trap: Misses that SGLT2 inhibitor-associated DKA can be euglycemic, leading to delayed diagnosis. SGLT2 inhibitors can cause euglycemic DKA, where ketoacidosis occurs with near-normal blood glucose because glucosuria lowers glucose while ketone production continues.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) block sodium-glucose cotransporter 2 in the proximal tubule — and USMLE Step 1 tests this class from angles students consistently miss. The biggest trap: students file gliflozins mentally as 'diabetes drugs only,' missing that the HF and CKD indications are tested even in non-diabetic patients. The result of SGLT2 blockade is lower blood glucose, osmotic diuresis, natriuresis, and a whole cascade of downstream effects that put this class at the intersection of renal physiology, cardiology, and endocrinology.

The exam tests SGLT2 inhibitors three ways: mechanism questions that ask what happens downstream of tubular blockade, complication questions that require you to recognize unusual presentations (especially euglycemic DKA in a stem that doesn't scream DKA), and outcomes/indications questions where you have to know these drugs are used for heart failure and CKD even in non-diabetic patients. That last angle trips up a lot of students who file gliflozins mentally under 'diabetes drugs only.' USMLE Step 1 will give you a patient with HFrEF or CKD and ask which drug reduces hospitalization — the answer is an SGLT2 inhibitor regardless of whether the patient has diabetes.

The trickiest part of this topic is euglycemic DKA. Students learn DKA means high glucose, so they miss it when a gliflozin patient presents with an anion gap acidosis and a glucose of 140. The glucosuria is actively pulling glucose out — so the glucose looks 'normal' while ketones are raging. Recognizing this pattern, and knowing why it happens mechanistically, is exactly what separates a 250+ scorer from someone who guesses on this stem.

From real student decks
73%have cards covering this topic
51%have mature cards

Common misconceptions

Common mistake
Wrong: DKA on SGLT2 inhibitors always presents with markedly elevated blood glucose.
Right: SGLT2 inhibitors can cause euglycemic DKA, where ketoacidosis occurs with near-normal blood glucose because glucosuria lowers glucose while ketone production continues.
Classic DKA teaching anchors the diagnosis to markedly elevated glucose (>250), but SGLT2 inhibitors break that rule by continuously excreting glucose into the urine. The result is a patient who is in true ketoacidosis — high anion gap, low bicarbonate, positive ketones — but with a glucose that looks near-normal, sometimes under 200. If you only check glucose and it's not sky-high, you'll miss the diagnosis; always check ketones and the anion gap in any gliflozin patient who presents sick.
Common mistake
Wrong: SGLT2 inhibitors benefit heart failure solely through glucose lowering.
Right: SGLT2 inhibitors reduce heart failure hospitalizations through osmotic diuresis, natriuresis, reduced preload/afterload, and possibly direct myocardial metabolic effects, independent of glycemic control.
It's tempting to explain every benefit of a diabetes drug through glucose lowering, but the heart failure data for SGLT2 inhibitors comes from trials that showed benefit even in non-diabetic HF patients — which immediately tells you glucose control isn't the whole story. The actual mechanisms include osmotic diuresis and natriuresis reducing preload, afterload reduction, and possibly a shift in myocardial fuel metabolism toward ketone oxidation. Understanding this also explains why the HF indication exists independently of the diabetes indication on the exam.
Common mistake
Gap: Misses that SGLT2 inhibitor-induced glucosuria predisposes to genital mycotic infections and Fournier's gangrene
SGLT2 inhibitors cause glucosuria that promotes genital mycotic infections (especially in women) and, rarely, Fournier's gangrene (necrotizing fasciitis of the perineum).
Glucosuria means the urogenital tract is bathed in glucose, which is a perfect growth medium for Candida. This is why genital mycotic infections are the most common adverse effect and are especially prominent in women. The high-yield extension is Fournier's gangrene — a rare but life-threatening necrotizing fasciitis of the perineum that has an FDA black box warning for this drug class; a Step 1 stem describing perineal pain, crepitus, or rapidly spreading infection in a gliflozin patient should immediately flag this diagnosis.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know the mechanism at the nephron level: SGLT2 blockade in the proximal tubule prevents glucose reabsorption, causing glucosuria, osmotic diuresis, and natriuresis — and understand how these effects translate to reduced blood pressure and volume.
  2. Recognize the adverse effect profile: glucosuria creates a sugar-rich urogenital environment that promotes genital mycotic infections (particularly in women) and, in rare severe cases, Fournier's gangrene (necrotizing fasciitis of the perineum).
  3. Identify euglycemic DKA: an SGLT2 inhibitor patient can develop true ketoacidosis with a high anion gap but near-normal blood glucose, because the drug is continuously excreting glucose even as ketone production accelerates.
  4. Apply the non-diabetes indications: SGLT2 inhibitors reduce cardiovascular death and HF hospitalizations in ASCVD, reduce progression in CKD (especially with albuminuria), and provide these benefits through glucose-independent mechanisms — so the indication holds even without diabetes.

Can you avoid these mistakes?

A 58-year-old man with type 2 diabetes on empagliflozin presents with nausea, vomiting, and malaise. Labs show pH 7.22, bicarbonate 12, anion gap 22, glucose 158 mg/dL, and positive serum ketones. What is the diagnosis, and why does the glucose appear near-normal?
A 65-year-old woman with HFrEF (EF 30%) and no diabetes is started on dapagliflozin. Her cardiologist says it will reduce her risk of hospitalization. A medical student asks how a diabetes drug helps someone without diabetes. What is the correct explanation?
Which adverse effect of SGLT2 inhibitors is directly caused by glucosuria, and what rare but surgical emergency involving the perineum must you know for the boards?
A patient with CKD (eGFR 45, urine albumin-to-creatinine ratio 400 mg/g) and hypertension but no diabetes asks if there are medications beyond ACE inhibitors that could slow CKD progression. Which drug class should you mention, and what is the mechanism of its renal benefit?

Related topics

Type 2 Diabetes Mellitus Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Thyroid (HPT) Axis Hypothalamic-Pituitary-Gonadal (HPG) Axis Hormone Signaling (Peptide vs Steroid)

See how your Anki deck covers this topic.

Upload your deck for a free audit →